EGFR and plasma cell myeloma: Intriguingly, AREG can be alternatively delivered via extracellular vesicles such as exosomes in the treatment‐naïve settings of multiple myeloma, non‐small‐cell lung cancer, and chronic myelogenous leukemia, each case activating the EGFR pathway in recipient cells without chemotherapy or SASP engagement in the TME (Corrado et al., 2016; Raimondo et al., 2019; Taverna et al., 2017).